ParAllele BioScience has inked a deal with Merck to use its genotyping technology to track the genetic variations that influence a person's susceptibility to cancer and their response to therapeutics. No financial terms were disclosed. "Merck has pioneered the application of genetics to cancer, and we are excited about this opportunity to broaden our collaborative relationship," said Hywel B. Jones, PhD, ParAllele's senior director of business development. "Our high-throughput technologies allow the determination of changes in copy number in tumors in a very efficient manner."
- read this press release for more